Literature DB >> 33999349

Pituitary Adenylate Cyclase-Activating Polypeptide Protects Against Cognitive Impairment Caused by Chronic Cerebral Hypoperfusion.

Xiaosu Guo1, Ye Tian1, Yaping Yang1, Shiping Li1, Li Guo2, Jiong Shi3,4,5.   

Abstract

BACKGROUND: Pituitary adenylate cyclase-activating polypeptide (PACAP) has beneficial effects in learning and memory. However, the mechanism by which PACAP improves cognitive impairment of vascular dementia (VaD) is not clear.
METHODS: We established a VaD model by bilateral common carotid stenosis (BCAS) to investigate the molecular mechanism of cognitive impairment. Protein levels of PACAP, Sirtuin 3 (Sirt3), brain-derived neurotrophic factor (BDNF), and postsynaptic density 95 (PSD-95) were assessed by Western blot. In vitro, oxygen glucose deprivation (OGD) was used to simulate the ischemia/hypoxia state. HT22 cells were transfected with Sirt3 knockdown and overexpression to study the relationship between PACAP, Sirt3, and BDNF. In vivo, PACAP was administered intranasally to assess its protective effects on BCAS.
RESULTS: The study showed that the levels of PACAP, Sirt3, BDNF, and PSD-95 were decreased in the BCAS model of VaD. PACAP increased the protein levels of Sirt3, BDNF, PSD-95, Bcl-2, and Bax under OGD condition in vitro. Sirt3 regulated BDNF and synaptic plasticity. Intranasal PACAP increased the protein levels of PAC1, Sirt3, BDNF, and PSD-95 in vivo.
CONCLUSIONS: This study provides evidence that PACAP regulates synaptic plasticity and plays an antiapoptotic role through Sirt3.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Apoptosis; BDNF; Cognitive impairment; PACAP; Sirt3; Vascular dementia

Mesh:

Substances:

Year:  2021        PMID: 33999349     DOI: 10.1007/s12035-021-02381-2

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  38 in total

Review 1.  PACAP as a neuroprotective factor in ischemic neuronal injuries.

Authors:  Seiji Shioda; Tomoya Nakamachi
Journal:  Peptides       Date:  2015-08-11       Impact factor: 3.750

2.  Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP.

Authors:  Agnieszka Dejda; Steve Bourgault; Ngoc Duc Doan; Myriam Létourneau; Alain Couvineau; Hubert Vaudry; David Vaudry; Alain Fournier
Journal:  Biochimie       Date:  2010-12-23       Impact factor: 4.079

3.  A novel peptide which stimulates adenylate cyclase: molecular cloning and characterization of the ovine and human cDNAs.

Authors:  C Kimura; S Ohkubo; K Ogi; M Hosoya; Y Itoh; H Onda; A Miyata; L Jiang; R R Dahl; H H Stibbs
Journal:  Biochem Biophys Res Commun       Date:  1990-01-15       Impact factor: 3.575

4.  The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32.

Authors:  D Vaudry; B J Gonzalez; M Basille; T F Pamantung; M Fontaine; A Fournier; H Vaudry
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

Review 5.  Therapeutic potential of PACAP for neurodegenerative diseases.

Authors:  Rongqiang Yang; Xin Jiang; Rui Ji; Lingbin Meng; Fuli Liu; Xiaolei Chen; Ying Xin
Journal:  Cell Mol Biol Lett       Date:  2015-06       Impact factor: 5.787

6.  Prevalence of dementia in the United States: the aging, demographics, and memory study.

Authors:  B L Plassman; K M Langa; G G Fisher; S G Heeringa; D R Weir; M B Ofstedal; J R Burke; M D Hurd; G G Potter; W L Rodgers; D C Steffens; R J Willis; R B Wallace
Journal:  Neuroepidemiology       Date:  2007-10-29       Impact factor: 3.282

Review 7.  Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research.

Authors:  A Arimura
Journal:  Regul Pept       Date:  1992-02-18

Review 8.  Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.

Authors:  David Vaudry; Anthony Falluel-Morel; Steve Bourgault; Magali Basille; Delphine Burel; Olivier Wurtz; Alain Fournier; Billy K C Chow; Hitoshi Hashimoto; Ludovic Galas; Hubert Vaudry
Journal:  Pharmacol Rev       Date:  2009-09       Impact factor: 25.468

Review 9.  Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases.

Authors:  Eun Hye Lee; Su Ryeon Seo
Journal:  BMB Rep       Date:  2014-07       Impact factor: 4.778

10.  Select cognitive deficits in vasoactive intestinal peptide deficient mice.

Authors:  Dipesh Chaudhury; Dawn H Loh; Joanna M Dragich; Arkady Hagopian; Christopher S Colwell
Journal:  BMC Neurosci       Date:  2008-07-10       Impact factor: 3.288

View more
  3 in total

1.  Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Protects Striatal Cells and Improves Motor Function in Huntington's Disease Models: Role of PAC1 Receptor.

Authors:  Irene Solés-Tarrés; Núria Cabezas-Llobet; Benjamin Lefranc; Jérôme Leprince; Jordi Alberch; David Vaudry; Xavier Xifró
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

2.  Overexpression of Brain- and Glial Cell Line-Derived Neurotrophic Factors Is Neuroprotective in an Animal Model of Acute Hypobaric Hypoxia.

Authors:  Maria S Gavrish; Mark D Urazov; Tatiana A Mishchenko; Victoria D Turubanova; Ekaterina A Epifanova; Victoria G Krut'; Alexey A Babaev; Maria V Vedunova; Elena V Mitroshina
Journal:  Int J Mol Sci       Date:  2022-08-27       Impact factor: 6.208

Review 3.  Female reproductive functions of the neuropeptide PACAP.

Authors:  Miklos Koppan; Zsuzsanna Nagy; Inez Bosnyak; Dora Reglodi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-20       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.